Understanding how the immune system fights IDH-mutant brain tumors with specific treatments
Interrogating Mechanisms of Anti-tumor Immunity in Human Subjects and Murine Models of IDH-Mutant Glioma Treated with All-Trans Retinoic Acid and PD-1 Inhibition
This project explores how certain treatments help the body's immune system fight a type of brain cancer called IDH-mutant glioma.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11126049 on NIH RePORTER |
What this research studies
This research aims to uncover how the immune system responds to specific therapies for IDH-mutant gliomas, a challenging form of brain cancer. We are looking at both laboratory models and information from human clinical trials to identify key immune signals and cells. Our goal is to understand why some tumors respond better to treatment than others. This deeper understanding will help guide the creation of new and more effective treatment options for patients.
Who could benefit from this research
Good fit: Patients with IDH-mutant diffuse gliomas, particularly those treated with all-trans retinoic acid and PD-1 inhibition, are relevant to this research.
Not a fit: Patients with other types of brain tumors or those not receiving the specific treatments mentioned may not directly benefit from this particular research.
Why it matters
Potential benefit: If successful, this work could lead to new ways to predict treatment response and develop more effective immunotherapies for IDH-mutant gliomas.
How similar studies have performed: This research builds upon existing knowledge of immunotherapy and brain tumor biology, seeking to identify specific mechanisms in IDH-mutant gliomas.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Amankulor, Nduka Mgbechinyere — University of Pennsylvania
- Study coordinator: Amankulor, Nduka Mgbechinyere
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.